

**BIOQUAL – Division of Primate Biology and Medicine**  
**Publications where BIOQUAL is acknowledged**

1. Bukh J, Thimme R, Meunier JC, Faulk K, Spangenberg HC, Chang KM, Satterfield W, Chisari FV, Purcell RH. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. *J Virol.* 2008 82:8183-95. PMID: 18550671
2. Goncalvez AP, Chien CH, Tubthong K, Gorshkova I, Roll C, Donau O, Schuck P, Yoksan S, Wang SD, Purcell RH, Lai CJ. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. *J Virol.* 2008 82:7009-21. PMID: 18480437
3. Vanwolleghem T, Bukh J, Meuleman P, Desombere I, Meunier JC, Alter H, Purcell RH, Leroux-Roels G. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. *Hepatology.* 2008 47:1846-55. PMID: 18452146
4. Bukh J, Engle RE, Govindarajan S, Purcell RH. Immunity against the GBV-B hepatitis virus in tamarins can prevent productive infection following rechallenge and is long-lived. *J Med Virol.* 2008 80:87-94. PMID: 18041000
5. Lai CJ, Goncalvez AP, Men R, Wernly C, Donau O, Engle RE, Purcell RH. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. *J Virol.* 2007 81:12766-74. PMID: 17881450
6. Sakai A, Takikawa S, Thimme R, Meunier JC, Spangenberg HC, Govindarajan S, Farci P, Emerson SU, Chisari FV, Purcell RH, Bukh J. In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells. *J Virol.* 2007;81:7208-19. PMID: 17409145
7. Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge. *Intervirology.* 2006;49:144-51. PMID: 16428890
8. Murray JM, Wieland SF, Purcell RH, Chisari FV. Dynamics of hepatitis B virus clearance in chimpanzees. *Proc Natl Acad Sci U S A.* 2005;102:17780-5. PMID: 16306261
9. Graff J, Nguyen H, Yu C, Elkins WR, St Claire M, Purcell RH, Emerson SU. The open reading frame 3 gene of hepatitis E virus contains a cis reactive element and encodes a protein required for infection of macaques. *J Virol.* 2005;79:6680-9. PMID: 15890906
10. Zhou YH, Purcell RH, Emerson SU. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. *Vaccine.* 2005;23:3157-65. PMID: 15837215
11. Barouch DH, Powers J, Truitt DM, Kishko MG, Arthur JC, Peyerl FW, Kuroda MJ, Gorgone DA, Lifton MA, Lord CI, Hirsch VM, Montefiori DC, Carville A, Mansfield KG, Kunstman KJ, Wolinsky SM, Letvin NL. Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. *Proc Natl Acad Sci USA.* 2005 May 31;102(22):8000-5.

12. Housman Dehghani, Charles R. Brown, Ronald Plishka, Alicia Buckler-White, and Vanessa M. Hirsch. The ITAM in Nef Influences Acute Pathogenesis of AIDS-Inducing Simian Immunodeficiency Viruses SIV<sub>sm</sub> and SIV<sub>agm</sub> without Altering Kinetics or Extent of Viremia. *J Virol.* 2002 May; 76(9): 4379–4389.
13. Goldstein S, Ourmanov I, Brown CR, Plishka R, Buckler-White A, Byrum R, Hirsch VM. Plateau levels of viremia correlate with the degree of CD4<sup>+</sup>-T-cell loss in simian immunodeficiency virus SIV<sub>agm</sub>-infected pigtailed macaques: variable pathogenicity of natural SIV<sub>agm</sub> isolates. *J Virol.* 2005 Apr;79(8):5153-62.
14. Nishimura Y, Igarashi T, Donau OK, Buckler-White A, Buckler C, Lafont BA, Goeken RM, Goldstein S, Hirsch VM, Martin MA. Highly pathogenic SHIVs and SIVs target different CD4<sup>+</sup> T cell subsets in rhesus monkeys, explaining their divergent clinical courses. *Proc Natl Acad Sci U S A.* 2004 Aug 17;101(33):12324-9.
15. Hirsch VM. What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS? *AIDS Rev.* 2004 Jan-Mar; 6(1):40-53.
16. Hirsch VM, Santra S, Goldstein S, Plishka R, Buckler-White A, Seth A, Ourmanov I, Brown CR, Engle R, Montefiori D, Glowczwskie J, Kunstman K, Wolinsky S, Letvin NL. Immune Failure in the Absence of Profound CD4<sup>+</sup> T-Lymphocyte Depletion in Simian Immunodeficiency Virus-Infected Rapid Progressor Macaques. *J Virol.* 2004 Jan;78(1):275-84.
17. Igarashi T, Imamichi H, Brown CR, Hirsch VM, Martin MA. The emergence and characterization of macrophage-tropic SIV/HIV chimeric viruses (SHIVs) present in CD4<sup>+</sup> T cell-depleted rhesus monkeys. *J Leukoc Biol.* 2003 Nov;74(5):772-80.
18. Hu J, Switzer WM, Foley BT, Robertson DL, Goeken RM, Korber BT, Hirsch VM, Beer BE. Characterization and comparison of recombinant simian immunodeficiency virus from drill (*Mandrillus leucophaeus*) and mandrill (*Mandrillus sphinx*) isolates. *J Virol.* 2003 Apr;77(8):4867-80.
19. Santra S, Barouch DH, Kuroda MJ, Schmitz JE, Krivulka GR, Beaudry K, Lord CI, Lifton MA, Wyatt LS, Moss B, Hirsch VM, Letvin NL. Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection. *J Virol.* 2002 Jun;76(12):6376-81.
20. Haddrick M, Brown CR, Plishka R, Buckler-White A, Hirsch VM, Ginsberg H. Biologic studies of chimeras of highly and moderately virulent molecular clones of simian immunodeficiency virus SIV<sub>sm</sub>PBj suggest a critical role for envelope in acute AIDS virus pathogenesis. *J Virol.* 2001 Jul;75(14):6645-59.
21. Barouch DH, Santra S, Kuroda MJ, Schmitz JE, Plishka R, Buckler-White A, Gaitan AE, Zin R, Nam JH, Wyatt LS, Lifton MA, Nickerson CE, Moss B, Montefiori DC, Hirsch VM, Letvin NL. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. *J Virol.* 2001 Jun;75(11):5151-8.
22. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, Hirsch V, Martin MA. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4<sup>+</sup> T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. *Proc Natl Acad Sci U S A.* 2001 Jan 16;98(2):658-63.

23. Goldstein S, Ourmanov I, Brown CR, Beer BE, Elkins WR, Plishka R, Buckler-White A, Hirsch VM. Wide range of viral load in healthy african green monkeys naturally infected with simian immunodeficiency virus. *J Virol.* 2000 Dec;74(24):11744-53.
24. Goldstein S, Brown CR, Dehghani H, Lifson JD, Hirsch VM. Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication. *J Virol.* 2000 Oct;74(20):9388-95.
25. Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. *Toxicol Appl Pharmacol.* 2004 Sep 1;199(2):151-61.
26. Gerschenson M, Poirier MC. Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure. *Ann N Y Acad Sci.* 2000 Nov;918:269-81.
27. Zhou YH, Purcell RH, Emerson SU. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. *Vaccine.* 2005 May 2;23(24):3157-65.
28. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. *Proc Natl Acad Sci U S A.* 2005 Mar 22;102(12):4560-5.
29. Huang FF, Sun ZF, Emerson SU, Purcell RH, Shivaprasad HL, Pierson FW, Toth TE, Meng XJ. Determination and analysis of the complete genomic sequence of avian hepatitis E virus (avian HEV) and attempts to infect rhesus monkeys with avian HEV. *J Gen Virol.* 2004 Jun;85(Pt 6):1609-18.
30. Purcell RH, Nguyen H, Shapiro M, Engle RE, Govindarajan S, Blackwelder WC, Wong DC, Prieels JP, Emerson SU. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. *Vaccine.* 2003 Jun 2;21(19-20):2607-15.
31. Zhang M, Emerson SU, Nguyen H, Engle R, Govindarajan S, Blackwelder WC, Gerin J, Purcell RH. Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques. *Vaccine.* 2002 Sep 10;20(27-28):3285-91.
32. Emerson SU, Purcell RH. Recombinant vaccines for hepatitis E. *Trends Mol Med.* 2001 Oct;7(10):462-6.
33. Reimann KA, Parker RA, Seaman MS, Beaudry K, Beddall M, Peterson L, Williams KC, Veazey RS, Montefiori DC, Mascola JR, Nabel GJ, Letvin NL. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. *J Virol.* 2005 Jul;79(14):8878-85.
34. Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, Lifton MA, Gorgone DA, Beaudry KR, Svehla K, Welcher B, Chakrabarti BK, Huang Y, Yang ZY, Mascola JR, Nabel GJ, Letvin NL. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. *J Virol.* 2005 May;79(10):6516-22.
35. Seaman MS, Santra S, Newberg MH, Philippon V, Manson K, Xu L, Gelman RS, Panicali D, Mascola JR, Nabel GJ, Letvin NL. Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A\*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys. *J Virol.* 2005 Apr;79(8):4580-8.

36. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, Sambor A, Chakrabarti BK, Huang Y, Bailer R, Koup RA, Mascola JR, Nabel GJ, Letvin NL. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.
37. Letvin NL, Huang Y, Chakrabarti BK, Xu L, Seaman MS, Beaudry K, Koriath-Schmitz B, Yu F, Rohne D, Martin KL, Miura A, Kong WP, Yang ZY, Gelman RS, Golubeva OG, Montefiori DC, Mascola JR, Nabel GJ. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. *J Virol.* 2004 78:7490-7.
38. Baig J, Levy DB, McKay PF, Schmitz JE, Santra S, Subbramanian RA, Kuroda MJ, Lifton MA, Gorgone DA, Wyatt LS, Moss B, Huang Y, Chakrabarti BK, Xu L, Kong WP, Yang ZY, Mascola JR, Nabel GJ, Carville A, Lackner AA, Veazey RS, Letvin NL. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. *J Virol.* 2002 Nov;76(22):11484-90.
39. Roberts A, Vogel L, Guarner J, Hayes N, Murphy B, Zaki S, Subbarao K. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. *J Virol.* 2005 Jan;79(1):503-11.
40. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature.* 2004 Apr 1;428(6982):561-4.
41. Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH. Human parainfluenza virus type 1 (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. *Vaccine.* 2005 Jun 9
42. Skiadopoulos MH, Tatem JM, Surman SR, Mitcho Y, Wu SL, Elkins WR, Murphy BR. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys. *Vaccine.* 2002 Mar 15;20(13-14):1846-52.
43. Skiadopoulos MH, Surman SR, Riggs JM, Collins PL, Murphy BR. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. *J Virol.* 2001 Nov;75(21):10498-504.
44. Whitehead SS, Hanley KA, Blaney JE Jr, Gilmore LE, Elkins WR, Murphy BR. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. *Vaccine.* 2003 Oct 1;21(27-30):4307-16.
45. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. *Am J Trop Med Hyg.* 2001 Nov;65(5):405-13.
46. Durbin AP, Elkins WR, Murphy BR. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection. *Vaccine.* 2000 May 8;18(22):2462-9.

47. Carruth LM, Zink MC, Tarwater PM, Miller MD, Li M, Queen LA, Mankowski JL, Shen A, Siliciano RF, Clements JE. SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy. *J Med Primatol.* 2005 Jun;34(3):109-21
48. Shen A, Zink MC, Mankowski JL, Chadwick K, Margolick JB, Carruth LM, Li M, Clements JE, Siliciano RF. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. *J Virol.* 2003 Apr;77(8):4938-49.